Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy - Innate

Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.